A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors
This was an open label, phase I (3 + 3 design), multi-centre study evaluating panobinostat in pediatric patients with refractory solid tumors.
Primary endpoints were to establish MTD, define and describe associated toxicities, including dose limiting toxicities (DLT) and to characterize its pharmacokinetics (PK). Secondary endpoints included assessing the anti-tumour activity of panobinostat, and its biologic activity, by measuring acetylation of histones in peripheral blood mononuclear cells.
Nine patients were enrolled and treated with intravenous panobinostat at a dosing level of 15 mg/m2 which was tolerated. Six were evaluable for adverse events. Two (33%) patients experienced Grade 3–4 thrombocytopenia, 1 (17%) experienced Grade 3 anemia, and 2 (33%) experienced Grade 3 neutropenia. Grade 4 drug related pain occurred in 2 (33%) of the patients studied. Two (33%) patients experienced a Grade 2 QTcF change (0.478 ± 0.006 ms). One cardiac DLT (T wave changes) was reported. PK values for 15 mg/m2 (n = 9) dosing were: Tmax 0.8 h, Cmax 235.2 ng/mL, AUC0–t 346.8 h ng/mL and t1/2 7.3 h. Panobinostat significantly induced acetylation of histone H3 and H4 at all time points measured when compared to pre-treatment samples (p < 0.05). Pooled quantitative Western blot data confirmed that panobinostat significantly induced acetylation of histone H4 at 6 h (p < 0.01), 24 h (p < 0.01) and 28–70 h (p < 0.01) post dose.
A significant biological effect of panobinostat, measured by acetylation status of histone H3 and H4, was achieved at a dose of 15 mg/m2. PK data and drug tolerability at 15 mg/m2 was similar to that previously published.
KeywordsPhase I Panobinostat Pediatric Refractory Relapsed Biomarkers
This research would not have been possible without the generous support of the You Are My Sunshine (YAMS) Foundation and the Kathleen Tinsley Fellowship.
This trial was sponsored by the Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG), 27 - 31 Wright Street, Clayton, VIC, 3168, Australia. This trial was supported by unrestricted funding and drug supply from Novartis Pharmaceuticals, Australia PTY Ltd., 54 Waterloo Road, Macquarie Park, NSW, 2113, Australia.
Compliance with ethical standards
Conflict of interest
The authors report no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Human and animal rights statement
This article does not contain any studies with animals performed by any of the authors.
Patient and/or their legal guardians must have signed a written informed consent form.
- 13.Irminger-Finger I, Siegel BD, Leung WC (1999) The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins. J Biol Chem 380(2):117–128Google Scholar
- 19.Coffey DC, Kutko MC, Glick RD et al (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 7(8):3591–3594Google Scholar
- 23.Prince HM, George D, Patnaik A et al (2007) Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumours and non-Hodgkins lymphoma. J Clin Oncol 25(18S):3500Google Scholar
- 35.Prince HM, Bishton M (2009) Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma. Hematol Meet Rep 3(1):33–38Google Scholar